<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03951194</url>
  </required_header>
  <id_info>
    <org_study_id>PRP- Perimenopause</org_study_id>
    <nct_id>NCT03951194</nct_id>
  </id_info>
  <brief_title>Autologous Platelet Rich Plasma (PRP) Intra Ovarian Infusion in Perimenopausal Women</brief_title>
  <acronym>PRP</acronym>
  <official_title>Investigating Improvement of Ovarian Function Following Autologous PRP Intra-ovarian Infusion in Perimenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genesis Athens Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National and Kapodistrian University of Athens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Genesis Athens Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autologous PRP intra ovarian infusion may improve ovarian response and women's hormonal&#xD;
      profile and may promote folliculogenesis in perimenopausal women.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This triple-blind Randomized Controlled Trial (RCT) aims to investigate the effectiveness of&#xD;
      autologous PRP intra ovarian infusion on improving ovarian tissue functionality and hormonal&#xD;
      profile of perimenopausal women. PRP is blood plasma prepared from fresh whole blood that has&#xD;
      been enriched with platelets. It is collected from peripheral veins and contains several&#xD;
      growth factors such as vascular endothelial growth factor (VEGF), epidermal growth factor&#xD;
      (EGF), platelet derived growth factor (PDGF), transforming growth factor (TGF) and other&#xD;
      cytokines all of which stimulate tissue proliferation and growth. PRP has been employed in&#xD;
      several medical conditions in Orthopedics, Dermatology, and Ophthalmology for wound healing.&#xD;
      It's efficacy in ovarian rejuvenation and reactivation and endometrial regeneration has not&#xD;
      been fully elucidated. This study aims to investigate the effect of autologous PRP intra&#xD;
      ovarian infusion on improving ovarian tissue functionality in perimenopausal women.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 13, 2019</start_date>
  <completion_date type="Anticipated">January 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Restoration of menstrual cycle regularity</measure>
    <time_frame>Three months</time_frame>
    <description>Regular Menstrual cycle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum FSH levels</measure>
    <time_frame>Follow-up period of three months entailing monthly evaluation</time_frame>
    <description>Serum FSH levels evaluated monthly for three consecutive months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum AMH levels</measure>
    <time_frame>Follow-up period of three months entailing monthly evaluation</time_frame>
    <description>Serum AMH levels evaluated monthly for three consecutive months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum LH levels</measure>
    <time_frame>Follow-up period of three months entailing monthly evaluation</time_frame>
    <description>Serum LH levels evaluated monthly for three consecutive months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Estradiol levels</measure>
    <time_frame>Follow-up period of three months entailing monthly evaluation</time_frame>
    <description>Serum etsradiol levels evaluated monthly for three consecutive months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Progesteron levels</measure>
    <time_frame>Follow-up period of three months entailing monthly evaluation</time_frame>
    <description>Serum progesterone levels evaluated monthly for three consecutive months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antral Follicle Count</measure>
    <time_frame>Follow-up period of three months entailing monthly evaluation</time_frame>
    <description>AFC evaluated monthly, on day 2 of the menstrual cycle, for three consecutive months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Infertility, Female</condition>
  <condition>Perimenopausal Disorder</condition>
  <condition>Menstrual Cycle Abnormal</condition>
  <arm_group>
    <arm_group_label>Participants receiving PRP treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Perimenopausal women, 40-50 years of age, treated with autologous PRP intra ovarian infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants receiving Platelet Free Plasma (PFP)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Perimenopausal women, 40-50 years of age, treated with autologous PRP intra ovarian infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Platelet Rich Plasma (PRP) intra ovarian infusion</intervention_name>
    <description>Autologous PRP intra ovarian infusion</description>
    <arm_group_label>Participants receiving PRP treatment</arm_group_label>
    <other_name>PRP</other_name>
    <other_name>Platelet Rich Plasma</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo: Autologous Platelet Free Plasma (PFP) intra ovarian infusion</intervention_name>
    <description>Autologous PFP intra ovarian infusion</description>
    <arm_group_label>Participants receiving Platelet Free Plasma (PFP)</arm_group_label>
    <other_name>PFP</other_name>
    <other_name>Platelet Free Plasma</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women â‰¥40 years of age, presenting with cycle irregularities while fulfilling at least&#xD;
             one of the respective two criteria: more than seven days difference in menstrual cycle&#xD;
             duration between two consecutive cycles OR, presence of a menstrual cycle duration&#xD;
             over sixty days and progressive elevation of FSH levels.&#xD;
&#xD;
          -  Discontinuation of any complementary/adjuvant treatment including hormone replacement,&#xD;
             acupuncture, and botanotherapy, for at least three months prior to recruitment.&#xD;
&#xD;
          -  Willing to comply with study requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any pathological disorder related to reproductive system anatomy&#xD;
&#xD;
          -  Amenorrhea&#xD;
&#xD;
          -  Endometriosis&#xD;
&#xD;
          -  Adenomyosis&#xD;
&#xD;
          -  Fibroids and adhesions&#xD;
&#xD;
          -  Infections in reproductive system&#xD;
&#xD;
          -  Current or previous diagnosis of cancer in reproductive system&#xD;
&#xD;
          -  History of familiar cancer in reproductive system&#xD;
&#xD;
          -  Severe male factor infertility&#xD;
&#xD;
          -  Prior referral for PGT&#xD;
&#xD;
          -  Ovarian inaccessibility&#xD;
&#xD;
          -  Previous POI diagnosis -Endocrinological disorders (Hypothalamus-&#xD;
&#xD;
          -  Pituitary disorders, thyroid dysfunction, diabetes mellitus, metabolic syndrome)&#xD;
&#xD;
          -  BMI&gt;30 kg/m2 or BMI&lt;18.5 kg/m2&#xD;
&#xD;
          -  Systematic autoimmune disorders&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agni Pantou, MD</last_name>
    <role>Study Director</role>
    <affiliation>Obstetrician Gynecologist</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mara Simopoulou, PhD</last_name>
    <phone>+306979234100</phone>
    <email>marasimopoulou@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Agni Pantou, MD, PhD Candidate</last_name>
    <email>agni.pantou@genesisathens.gr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Genesis AC</name>
      <address>
        <city>Athens</city>
        <zip>15232</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agni Pantou, MD, PhD Candidate</last_name>
      <email>agni.pantou@genesisathens.gr</email>
    </contact>
    <contact_backup>
      <last_name>Konstantinos Pantos, MD,PhD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 25, 2017</study_first_submitted>
  <study_first_submitted_qc>May 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2019</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

